As reported on CNET, parents and caregivers now have a new option to help monitor children’s blood sugar levels at home. The US Food and Drug Administration (FDA) has cleared…
As reported on BioSpace, Eli Lilly is moving closer to expanding the use of its oral GLP‑1 receptor agonist orforglipron, marketed as Foundayo, into type 2 diabetes (T2D), following encouraging…
Editor's Note: Patient Worthy is honored to present this article, shared with us by our friends at the Steatotic Liver Foundation (formerly the Fatty Liver Foundation). To see this article…
A groundbreaking advance in diabetes care has emerged from recent clinical research: a new cell therapy has successfully restored natural insulin production in 83% of participants living with diabetes. This…
According to a recent report in Healio News, the GLP-1 agonists are medications developed primarily to control blood sugar levels for type two diabetes. About the FLOW Clinical Trial The…
According to a story from Healio, analysis of the FDA Adverse Events Reporting System database indicates that tirzepatide has a superior safety profile when compared to GLP-1 inhibitors that have…
According to a story from Healio, Joe Luvisi, MD, discusses how AI can be utilized to predict a patient's response to anti-VEGF therapy in patients living with diabetic macular edema.…
Ruud Dobber, executive VP of biopharmaceuticals at AstraZeneca was quoted in a press release dated saying that type 2 diabetes is on the rise in adolescents and younger children with…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
